News

Investor Interest Surges in Palantir Technologies Options

Investor Interest Surges in Palantir Technologies Options

Investor Sentiment Around Palantir Technologies Options

Recently, investors have shown a significant bullish trend towards Palantir Technologies. With high-profile traders stepping into the options market, it’s evident that there’s considerable confidence in the company's future performance.

Analyzing Options Activity

Trade Overview

During recent analysis, there were 346 trades involving Palantir Technologies (PLTR) options recorded, revealing a consistent interest among savvy investors. Remarkably, around 44% of these trades were initiated with bullish expectations, while 34% were bearish.

Investment Breakdown

Analyzing the data provides a clearer picture: a total of 109 put options were traded, amounting to $7,871,951, contrasted by 237 call options that reflected a substantial investment of $17,326,242. This disparity indicates strong confidence in the stock's upward potential.

Price Movement Projections

In examining the volume and open interest in these contracts, big players seem to anticipate price movements within a range from $35.00 to $240.00 for Palantir Technologies over the last quarter. Such forecasts often guide the trading strategies of less experienced investors.

Understanding Volume and Open Interest

Importance of Trading Metrics

Traders often rely on volume and open interest as crucial indicators of market activity related to Palantir Technologies options. This data provides invaluable insights into liquidity and investor interest for various strike prices.

Recent Trends in Options Activity

The recent trends depict the evolution of volume and open interest, particularly showing how whales have engaged with both call and put options within the $35.00 to $240.00 range during the past month.

Detailed Options Activity Analysis: Last 30 Days

Notable Options Traded

Among the most notable recent trades, various call options were detected indicating a mix of sentiments:

  • **Symbol:** PLTR | **Type:** CALL | **Trade Type:** SWEEP | **Price:** $12.55 | **Strike Price:** $180.00 | **Total Trade Price:** $485.7K | **Open Interest:** 14.2K
  • **Symbol:** PLTR | **Type:** CALL | **Trade Type:** SWEEP | **Price:** $10.70 | **Strike Price:** $185.00 | **Total Trade Price:** $413.7K | **Open Interest:** 4.7K
  • **Symbol:** PLTR | **Type:** PUT | **Trade Type:** SWEEP | **Price:** $2.95 | **Strike Price:** $170.00 | **Total Trade Price:** $125.0K | **Open Interest:** 706

Company Background: Palantir Technologies

Palantir Technologies is a leading software company specializing in data analytics to streamline operations for commercial and government sectors alike. It operates primarily through its Foundry and Gotham platforms and is committed to collaborating with entities aligned with Western values. Founded in 2003 and becoming publicly listed in 2020, Palantir has established itself as an industry leader in leveraging data.

Current Market Position of Palantir Technologies

  • As of now, PLTR's trading volume stands at 118,728,247, with a price appreciation of 7.13%, bringing its value to $172.11.
  • Indicators suggest that the stock may be approaching overbought conditions, signaling traders to exercise caution.
  • The upcoming earnings report has been anticipated within the next 90 days, which could provide further clarity on the company's direction.

Analyst Opinions on Palantir Technologies

Recently, professional analysts have evaluated Palantir Technologies with a consensus price target averaging $172.8. This indicates overall cautious optimism about the stock’s future:

  • An analyst from Morgan Stanley maintains a neutral stance with a price target set at $155.
  • Citigroup echoes a neutral outlook, setting their price target at $177.
  • Reflecting some concerns, Piper Sandler has altered its rating to Overweight, with a reevaluated price target of $170.
  • B of A Securities continues to uphold a Buy rating, with a target of $180.
  • Finally, Piper Sandler maintains an Overweight rating, suggesting a higher target price of $182.

Engaging in options trading can present amplified risks yet equally high rewards. Savvy traders often find value in ongoing education, strategic adaptations, and remaining informed on market changes. Keeping an eye on Palantir Technologies' options trades proves essential for staying ahead in this competitive landscape.

Frequently Asked Questions

What is Palantir Technologies' current stock price?

As of the latest information, the stock price of Palantir Technologies (PLTR) is approximately $172.11.

What trends are seen in Palantir's options trading?

A noticeable bullish trend has emerged, with a substantial number of call options being traded over the past month.

How do volume and open interest influence options trading?

Higher volume and open interest usually indicate increased interest and liquidity in a stock's options, influencing trading decisions.

What do analysts think about Palantir Technologies?

Analysts generally have a cautiously optimistic outlook, with various ratings and price targets reflecting moderate expectations.

What opportunities arise from trading Palantir Technologies options?

Traders often leverage options trading to maximize potential profits, especially with anticipated price movements based on market conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 113

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 260

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 256

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 68

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 194

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 20

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 147

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 277

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 127

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading

Top 5 Most Recently Viewed Articles

Music Licensing, Inc. Enhances Transparency with Auditing Plans

Updated Category News Views 136

Pro Music Rights Embarks on a New Financial Journey In an important move towards greater accountability, Music Licensing, Inc. (OTC: SONG), also recognized as Pro Music Rights, has announced its intention to hire a PCAOB-registered audit firm to perform annual audits. This step reflects the company's dedication to enhancing the integrity of its financial reporting and...

Continue Reading
The Importance of Foreign Investment in China's Growth Strategy

Updated Category News Views 200

The Importance of Foreign Investment in China's Growth Strategy Foreign investment plays a pivotal role in shaping China’s robust economic landscape, a sentiment echoed by a growing number of experts and stakeholders. A recent wave of inquiries about the necessity of foreign investment for China's ongoing development highlights this matter as a crucial topic. This...

Continue Reading
CityBee Expands Operations with Major Lease Extensions

Updated Category News Views 313

Significant Lease Extensions for CityBee at Cuprum CityBee, a prominent joint venture in the UK office sector, has recently achieved a significant milestone by securing two critical lease extensions at Cuprum. This exciting development, involving major tenants, highlights when the future of office spaces is considered, the increasing demand for high-quality and...

Continue Reading
Exploring the Future of Geospatial Solutions in Key Industries

Updated Category News Views 319

Geospatial Solutions: A Market on the Rise The global geospatial solution market is gearing up for remarkable growth, estimated to reach approximately USD 545.7 billion soon and surpassing an impressive USD 2,061.3 billion in the coming years. This upward trajectory represents a compound annual growth rate (CAGR) of 14.2% projected between now and 2035, showcasing a...

Continue Reading
Progyny's Challenges and Insights into Fertility Benefits Landscape

Updated Category News Views 100

Progyny got rocked back in 2024 when news broke that Amazon ditched them for Maven Clinic's fertility benefits. You could feel the desks shuddering as this big player made its move, shaking up the entire landscape. This shift was like a punch to the gut for Progyny, especially since Amazon had been a key client. That loss wasn’t just some random hit; it was a direct...

Continue Reading